Over the past two decades, inhibitors of the polycomb repressor complex (PRC) have been driven from bench to bedside. New chemical compounds targeting the RING1B in polycomb repressor complex 1 (PRC1) add important tools to regulate polycomb functions.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
He, Y. et al. Nat. Chem. Biol. 13, 389–395 (2017).
Knutson, S. K. et al. Mol. Cancer Ther. 13, 842–854 (2014).
Shukla, S. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-021-00815-5 (2021).
Piunti, A. & Shilatifard, A. Nat. Rev. Mol. Cell Biol. 22, 326–345 (2021).
Fursova, N. A. et al. Mol. Cell 74, 1020–1036.e8 (2019).
Kundu, S. et al. Mol. Cell 3, 432–446 (2018).
Tsherniak, A. et al. Cell 170, 564–576.e16 (2017).
Gao, H., Sun, X. & Rao, Y. ACS Med. Chem. Lett. 11, 237–240 (2020).
Stuckey, J. I. et al. Nat. Chem. Biol. 12, 180–187 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.P.P. is an employee of AbbVie Inc.
Rights and permissions
About this article
Cite this article
Plotnik, J.P. Fighting PRC1 via the RING. Nat Chem Biol 17, 753–754 (2021). https://doi.org/10.1038/s41589-021-00819-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-021-00819-1
